Skip to nav Skip to content
Facebook Twitter LinkedIn Email

Infectious Diseases Funding Requests in the President’s FY 2025 Budget

IDSA is encouraged that the president’s FY 2025 Budget Request proposes deeper investments in several key IDSA priorities, including the CDC Antibiotic Resistance Solutions Initiative (to prevent, detect, track and contain antimicrobial resistance) and the National Institute of Allergy and Infectious Diseases, though IDSA is advocating for even larger funding increases for these priorities. Additionally, the president’s budget request includes an IDSA-championed proposal aligned with the bipartisan Pioneering Antimicrobial Solutions to End Upsurging Resistance (PASTEUR) Act to strengthen antimicrobial research and development through the use of federal contracts that delink payments for novel antimicrobials from their use.  

IDSA was disappointed that funding for the Bio-Preparedness Workforce Pilot Program at the Health Resources and Services Administration was not included in the president’s budget. The pilot program would help to recruit and retain ID/HIV health care professionals by providing loan repayment to those who serve in health professional shortages areas or federal facilities such as Ryan White clinics or VA facilities. IDSA calls on Congress to provide funding for the pilot program in FY 2025.

IDSA is advocating for increased investments for the full breadth of domestic and global ID programs.

ID Funding Proposals in the President’s FY 2025 Budget

Department of Health and Human Services 
Centers for Disease Control and Prevention
•    $9.683 billion for CDC, an increase of $500 million over FY 2023; 
•    $207 million for the Antibiotic Resistance Solutions Initiative, a $10 million increase;
•    $24 million for CDC National Healthcare Safety Network, level funding;
•    $40 million for CDC Advanced Molecular Detection, level funding;
•    $692.8 million for CDC global  health overall, level funding; and $293.2 million for CDC global health protection, level funding;
•    $23 million for the Infectious Diseases and Opioid Program, level funding.

National Institutes of Health
•    $48.3 billion for NIH overall, a $871.5 million increase;
•    $6.581 billion for NIAID overall, a $19.6 million increase;  
•    $95.4 million for the Fogarty International Center, a $300,000 increase.

Administration for Strategic Preparedness and Response/Biomedical Advanced Research and Development Authority
•    $970 million for BARDA overall, a $20 million increase, including $160 million for the Broad-Spectrum Antimicrobials/Combating Antibiotic-Resistant Bacteria programs;
•    $820 million for Project Bioshield, level funding;
•    Language that aligns with the PASTEUR Act to revitalize antimicrobial R&D by delinking antimicrobial revenue from volume of sales. 

State Department and U.S. Agency for International Development
•    $394.5 million for the USAID global tuberculosis program, level funding;
•    $90 million for USAID global health security, level funding;
•    $394.5 million for global TB, level funding;
•    $4.935 billion for the President’s Emergency Plan for AIDS Relief, level funding; 
•    $1.19 billion for the Global Fund to Fight AIDS, TB and Malaria, a 40.5% cut below the FY 2023 level; 
•    $20 million for the USAID Global Health Worker Initiative, a new program that was first proposed in the FY 2024 president’s Budget Request.

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.